DR. GEORGE L. FOLTIN, M.D.
Medical Practice in New York, NY
License number
New York 151386
Category
Osteopathic Medicine
Type
Emergency Medicine
License number
New York 151386
Category
Osteopathic Medicine
Type
Pediatric Emergency Medicine
License number
New York 151386
Category
Medical Practice
Type
Pediatrics
Address
Address
456 First Ave SUITE 9W25, New York, NY 10003
Phone
(212) 562-3161
Personal information
See more information about GEORGE L. FOLTIN at radaris.comName
Address
Phone
1 Irving Pl APT V19F, New York, NY 10003
1 Irving Pl, New York, NY 10003
1 Irving Pl, New York, NY 10003
205 95Th St, New York, NY 10128
3468 Silverton Ave, Wantagh, NY 11793
Professional information
George Foltin, Md
Location:
Greater New York City Area
Industry:
Hospital & Health Care
Dr. George L Foltin, Brooklyn NY - MD (Doctor of Medicine)
Specialties:
Pediatric Emergency Medicine
Address:
977 48Th St, Brooklyn 11219
BELLEVUE HOSPITAL DEPARTMENT OF EMERGENCY SERVICES
462 1St Ave SUITE V19F, New York 10016
(212) 562-3161 (Phone)
BELLEVUE HOSPITAL DEPARTMENT OF EMERGENCY SERVICES
462 1St Ave SUITE V19F, New York 10016
(212) 562-3161 (Phone)
Certifications:
Emergency Medicine, 1989, Pediatric Emergency Medicine, 1992, Pediatrics, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
State University of New York At Buffalo
Graduated: 1981
Chldns
Graduated: 1984
State University of New York At Buffalo
Graduated: 1981
Chldns
Graduated: 1984
Compositions And Methods Relating To Modulation Of Immune System Components
US Patent:
2010001, Jan 21, 2010
Filed:
Mar 22, 2007
Appl. No.:
12/225459
Inventors:
Tracy Hussell - Kent, GB
James W. Larrick - Sunnyvale CA, US
George L. Foltin - New York NY, US
James W. Larrick - Sunnyvale CA, US
George L. Foltin - New York NY, US
International Classification:
A61K 39/395, A61K 38/16
US Classification:
4241341, 514 12
Abstract:
A composition comprising a molecular blockade agent to a costimulatory molecule which costimulatory molecule satisfies the following criteria: a. absent in naÊve or resting T-lymphocytes; b. inducible; c. expressed; and d. prominent at the height of an immunopathological response, such as a disease/condition response. Preferably, the costimulatory molecule is OX40 and the molecular blockade agent is an antibody or antibody fragment having antibody activity to OX40. Further, the system may involve modulation of the molecular signal pathway of the aforesaid costimulatory molecule.